Search

Your search keyword '"García-Marco, José A."' showing total 223 results
Start Over Author "García-Marco, José A."
223 results on '"García-Marco, José A."'

1. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Author

Abrisqueta, Pau, González-Barca, Eva, Ferrà, Christelle, Ríos-Herranz, Eduardo, Fernández de la Mata, Margarita, Delgado, Julio, Andreu, Rafael, Hernández-Rivas, José Ángel, Terol, María José, Navarro, Almudena, Vidriales, M. Belén, Baltasar, Patricia, De la Serna, Javier, Ramírez, Ángel, Ballester, Carmen, Moreno, Carol, García-Marco, José Antonio, Córdoba, Raúl, Yáñez, Lucrecia, Casado, Luís Felipe, González, Marcos, and Bosch, Francesc

Published
2024
Full Text
View/download PDF

2. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, Milic, Natasa, Chatzikonstantinou, Thomas, Scarfò, Lydia, Otasevic, Vladimir, Rajovic, Nina, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Baile Gonzales, Monica, Capasso, Antonella, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Correa, Juan Gonzalo, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Dimou, Maria, Doubek, Michael, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Lopez-Garcia, Alberto, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicińska, Elżbieta, Kater, Arnon P., Kersting, Sabina, Koren-Michowitz, Maya, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Fresa, Alberto, Levin, Mark-David, Mayor Bastida, Carlota, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Nunes, Raquel, Olivieri, Jacopo, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Reda, Gianluigi, Rigolin, Gian Matteo, Shrestha, Amit, Šimkovič, Martin, Smirnova, Svetlana, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Te Raa, Doreen, Tomic, Kristina, Tonino, Sanne, Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Vukovic, Vojin, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, Segundo, Lucrecia Yáñez San, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Carrier, Marc, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2022
Full Text
View/download PDF

3. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2021
Full Text
View/download PDF

5. Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

Author

Jiménez, Isabel, Tazón-Vega, Bárbara, Abrisqueta, Pau, Nieto, Juan C., Bobillo, Sabela, Palacio-García, Carles, Carabia, Júlia, Valdés-Mas, Rafael, Munuera, Magdalena, Puigdefàbregas, Lluís, Parra, Genís, Esteve-Codina, Anna, Franco-Jarava, Clara, Iacoboni, Gloria, Terol, María José, García-Marco, José Antonio, Crespo, Marta, and Bosch, Francesc

Published
2021
Full Text
View/download PDF

6. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Author

Visentin, Andrea, primary, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Antic, Darko, additional, Baile, Mónica, additional, Baliakas, Panagiotis, additional, Besikli‐Dimou, Sotiria, additional, Bron, Dominique, additional, Chatzileontiadou, Sofia, additional, Cordoba, Raul, additional, Correa, Juan‐Gonzalo, additional, Cuéllar‐García, Carolina, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Delgado, Julio, additional, Dimou, Maria, additional, Donaldson, David, additional, Catherwood, Mark, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, Eichhorst, Barbara, additional, Elashwah, Salma, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Frederiksen, Henrik, additional, Fürstenau, Moritz, additional, García‐Marco, José A., additional, García‐Serra, Rocío, additional, Collado, Rosa, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Glenthøj, Andreas, additional, da Silva, Maria Gomes, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández‐Rivas, José Ángel, additional, Herold, Tobias, additional, Innocenti, Idanna, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark‐David, additional, Lista, Enrico, additional, Lopez‐Garcia, Alberto, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca R., additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Niemann, Carsten U., additional, Rodrigues, Raquel Nunes, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Qvist, Kristian, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Tadmor, Tamar, additional, Capasso, Antonella, additional, Del Poeta, Giovanni, additional, Gutwein, Odit, additional, Karlsson, Linda Katharina, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Reda, Gianluigi, additional, Saghumyan, Gevorg, additional, Shrestha, Amit, additional, Te Raa, Doreen, additional, Tonino, Sanne H., additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, van Kampen, Roel, additional, Wasik‐Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Pocali, Barbara, additional, Vandenberghe, Elisabeth, additional, Iyengar, Sunil, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Cuneo, Antonio, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2023
Full Text
View/download PDF

7. Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study

Author

Loscertales, Javier, primary, Abrisqueta-Costa, Pau, additional, Gutierrez, Antonio, additional, Hernández-Rivas, José Ángel, additional, Andreu-Lapiedra, Rafael, additional, Mora, Alba, additional, Leiva-Farré, Carolina, additional, López-Roda, María Dolores, additional, Callejo-Mellén, Ángel, additional, Álvarez-García, Esther, additional, and García-Marco, José Antonio, additional

Published
2023
Full Text
View/download PDF

9. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p< 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2024
Full Text
View/download PDF

11. CCR Translation for This Article from Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation

Author

Redondo-Muñoz, Javier, primary, Escobar-Díaz, Elizabeth, primary, Hernández del Cerro, Mercedes, primary, Pandiella, Atanasio, primary, Terol, María José, primary, García-Marco, José A., primary, and García-Pardo, Angeles, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation

Author

Redondo-Muñoz, Javier, primary, Escobar-Díaz, Elizabeth, primary, Hernández del Cerro, Mercedes, primary, Pandiella, Atanasio, primary, Terol, María José, primary, García-Marco, José A., primary, and García-Pardo, Angeles, primary

Published
2023
Full Text
View/download PDF

13. Sequential Quantification of T-Cell Receptor Excision Circles (TREC) and K-Deleting Recombination Excision Circles (KREC) in Allogeneic HSCT Recipients

Author

de Miguel, Carlos, primary, Briansó, Ferran, additional, Trillo, Rosalia Alonso, additional, Martín-Buitrago, Lucía Nuñez, additional, Martínez-Muñoz, María Esther, additional, Bautista, Guiomar, additional, Manchado-Perdiguero, Carlos, additional, García-Marco, José Antonio, additional, Sánchez-Peral, Ali, additional, and Duarte, Rafael F., additional

Published
2023
Full Text
View/download PDF

15. Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders

Author

Kwon, Mi, Bautista, Guiomar, Balsalobre, Pascual, Sánchez-Ortega, Isabel, Serrano, David, Anguita, Javier, Buño, Ismael, Fores, Rafael, Regidor, Carmen, García Marco, José A., Vilches, Carlos, de Pablo, Rosario, Fernández, Manuel N., Gayoso, Jorge, Duarte, Rafael, Díez-Martín, José Luis, and Cabrera, Rafael

Published
2014
Full Text
View/download PDF

16. PLCG1 mutations in cutaneous T-cell lymphomas

Author

Vaqué, José P., Gómez-López, Gonzalo, Monsálvez, Verónica, Varela, Ignacio, Martínez, Nerea, Pérez, Cristina, Domínguez, Orlando, Graña, Osvaldo, Rodríguez-Peralto, José L., Rodríguez-Pinilla, Socorro M., González-Vela, Carmen, Rubio-Camarillo, Miriam, Martín-Sánchez, Esperanza, Pisano, David G., Papadavid, Evangelia, Papadaki, Theodora, Requena, Luis, García-Marco, José A., Méndez, Miriam, Provencio, Mariano, Hospital, Mercedes, Suárez-Massa, Dolores, Postigo, Concepción, San Segundo, David, López-Hoyos, Marcos, Ortiz-Romero, Pablo L., Piris, Miguel A., and Sánchez-Beato, Margarita

Published
2014
Full Text
View/download PDF

17. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Author

Ferra, Christelle, Terol, María José, Marquet Palomanes, Juan, Ramírez Payer, Angel, Moreno, Carol, Osorio, Santiago, De la Cruz, Fátima, Garcia-Marco, Jose A., Ortiz, Macarena, Rios Herranz, Eduardo, Magnano, Laura, Iraheta, Sandra, Puerta, Jose Manuel, de la Serna, Javier, Smucler, Alicia, Arguiñano, Jose Maria, Loscertales, Javier, Muiña, Begoña, Fernández, Rubén, García, Tomas, Márquez, José A., Muntañola Prat, Ana, Perez Persona, Ernesto, Yáñez, Lucrecia, Pérez-Encinas, Manuel, González Díaz, Marcos, Caballero, Gonzalo, Andreu, María Angeles, Andreu, Rafael, Ruiz-Zorrilla, Ana, Moreno, Diana, and Baltasar, Patricia

Published
2022
Full Text
View/download PDF

18. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, Scarfò, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Mónica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet Palomanes, Juan, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Miras Calvo, Fatima, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Raa, Doreen te, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca Ciocan, Oana, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van Der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yáñez, Lucrecia, Yassin, Mohamed A, Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2022
Full Text
View/download PDF

19. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

Author

Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, García-Marco, Jose A., González, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzó, Encarna, Jarque, Isidro, Muntañola, Ana, Constants, Mireia, Escoda, Lourdes, Calvo, Xavier, Bobillo, Sabela, Montoro, José Bruno, Montserrat, Emili, and Bosch, Francesc

Published
2013
Full Text
View/download PDF

20. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Gonzales, Monica Baile, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Poeta, Giovanni Del, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, García-Marco, José A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Silva, Maria Gomes, additional, Gutwein, Odit, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Bastida, Carlota Mayor, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Raa, Doreen Te, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Spek, Ellen Der, additional, Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

22. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Author

Roeker, Lindsey E., primary, Eyre, Toby A., additional, Thompson, Meghan C., additional, Lamanna, Nicole, additional, Coltoff, Alexander R., additional, Davids, Matthew S., additional, Baker, Peter O., additional, Leslie, Lori, additional, Rogers, Kerry A., additional, Allan, John N., additional, Cordoba, Raul, additional, Lopez-Garcia, Alberto, additional, Antic, Darko, additional, Pagel, John M., additional, Martinez-Calle, Nicolas, additional, García-Marco, José Antonio, additional, Hernández-Rivas, Jose-Ángel, additional, Miras, Fatima, additional, Coombs, Catherine C., additional, Österborg, Anders, additional, Hansson, Lotta, additional, Seddon, Amanda N., additional, López Jiménez, Javier, additional, Wilson, Matthew R., additional, El-Sharkawi, Dima, additional, Wojenski, Daniel, additional, Ma, Shuo, additional, Munir, Talha, additional, Valenciano, Susana, additional, Seymour, Erlene, additional, Barr, Paul M., additional, Pu, Jeffrey, additional, Patten, Piers E. M., additional, Perini, Guilherme F., additional, Huntington, Scott F., additional, Parry, Helen, additional, Sundaram, Suchitra, additional, Skarbnik, Alan, additional, Kamdar, Manali, additional, Jacobs, Ryan, additional, Walter, Harriet, additional, Walewska, Renata, additional, Broom, Angus, additional, Lebowitz, Sonia, additional, Isaac, Krista M., additional, Portell, Craig A., additional, Ahn, Inhye E., additional, Ujjani, Chaitra S., additional, Shadman, Mazyar, additional, Skånland, Sigrid S., additional, Chong, Elise A., additional, and Mato, Anthony R., additional

Published
2021
Full Text
View/download PDF

24. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

Author

González-Rincón, Julia, primary, Garcia-Vela, José A., additional, Gómez, Sagrario, additional, Fernández-Cuevas, Belén, additional, Nova-Gurumeta, Sara, additional, Pérez-Sanz, Nuria, additional, Alcoceba, Miguel, additional, González, Marcos, additional, Anguita, Eduardo, additional, López-Jiménez, Javier, additional, González-Barca, Eva, additional, Yáñez, Lucrecia, additional, Pérez-Persona, Ernesto, additional, de la Serna, Javier, additional, Fernández-Zarzoso, Miguel, additional, Deben, Guillermo, additional, Peñalver, Francisco J., additional, Fernández, María C., additional, de Oteyza, Jaime Pérez, additional, Andreu, M. Ángeles, additional, Ruíz-Guinaldo, M. Ángeles, additional, Paz-Arias, Raquel, additional, García-Malo, M. Dolores, additional, Recasens, Valle, additional, Collado, Rosa, additional, Córdoba, Raúl, additional, Navarro-Matilla, Belén, additional, Sánchez-Beato, Margarita, additional, and García-Marco, José A., additional

Published
2021
Full Text
View/download PDF

26. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults

Author

Gonzalo-Daganzo, Rosa, Regidor, Carmen, Martín-Donaire, Trinidad, Rico, Miguel Angel, Bautista, Guiomar, Krsnik, Isabel, Forés, Rafael, Ojeda, Emilio, Sanjuán, Isabel, García-Marco, José A., Navarro, Belén, Gil, Santiago, Sánchez, Rocío, Panadero, Nuria, Gutiérrez, Yolanda, García-Berciano, Miguel, Pérez, Nuria, Millán, Isabel, Cabrera, Rafael, and Fernández, Manuel N.

Published
2009
Full Text
View/download PDF

27. Additional file 2 of Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

Author

Jiménez, Isabel, Tazón-Vega, Bárbara, Abrisqueta, Pau, Nieto, Juan C., Sabela Bobillo, Palacio-García, Carles, Carabia, Júlia, Valdés-Mas, Rafael, Munuera, Magdalena, Lluís Puigdefàbregas, Genís Parra, Esteve-Codina, Anna, Franco-Jarava, Clara, Iacoboni, Gloria, Terol, María José, García-Marco, José Antonio, Crespo, Marta, and Bosch, Francesc

Abstract

Additional file 2: Supplementary Table S1. Monoclonal antibodies (mAbs). Supplementary Table S7. Highlighted dysregulated genes in T CLL cells at progression. Supplementary Figure S1. Longitudinal analysis of the CCF of CNVs from paired B-CLL cells at diagnosis and progression before treatment. Comparison of the CCF with 95% CI for each CNV detected per patient (n = 10) between diagnosis and progression. Significantly increased (red lines) and stable CCF (grey lines) are shown. Recurrent CNVs in CLL (del(13q), del(11q), del(17p) and +[12]) are plotted with bold lines and labeled with CNV name: stable CCF (bold black) is shown. Supplementary Figure S2. CD8+ T cell differentiation subsets and PD1 expression in CD8+ T cells from progressing and non-progressing CLL patients. a CD4/CD8 ratio in progressing (n = 19) and non-progressing patients (n = 10) at diagnosis and progression or non-progression. b Absolute numbers of CD8+ T cell differentiation subsets (naive: CCR7+CD45RA+; central memory, CM: CCR7+CD45RA−; effector memory, EM: CCR7−CD45RA− and EM CD45RA+, EMRA: CCR7−CD45RA+) in progressing (n = 19) and non-progressing patients (n = 10) at diagnosis and progression or non-progression. c Absolute numbers of PD1+CD8+ T cells in progressing (left, n = 19) and non-progressing patients (middle, n = 10) at diagnosis and progression or non-progression. Fold change of PD1+CD8+ T cells between time points comparing progressing and non-progressing patients (right). d Percentage of PD1+CD244+ CD8+ T cells in progressing (left, n = 12) and non-progressing patients (middle, n = 9) at diagnosis and progression or non-progression. Fold change of PD1+CD244+CD8+ T cells between time points comparing progressing and non-progressing patients (right). e Percentage of PD1+ 160+ CD8+ T cells in progressing (left, n = 12) and non-progressing patients (middle, n = 9) at diagnosis and progression or non-progression. Fold change of PD1+CD160+CD8+ T cells between time points comparing progressing and non-progressing patients (right). f Density plots of PD1, CD160 and CD244 coexpression in CD8+ T cells in representative patients at diagnosis and progression and at diagnosis and non-progression. Graphs show mean ± SEM or paired values (*P

Published
2021
Full Text
View/download PDF

28. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Author

Roeker, Lindsey E, Scarfo, Lydia, Chatzikonstantinou, Thomas, Abrisqueta, Pau, Eyre, Toby A., Cordoba, Raul, Muntañola Prat, Ana, Villacampa, Guillermo, Leslie, Lori A., Koropsak, Michael, Quaresmini, Giulia, Allan, John N., Furman, Richard R., Bhavsar, Erica B, Pagel, John M., Hernandez-Rivas, Jose Angel, Patel, Krish, Motta, Marina, Bailey, Neil, Miras, Fatima, Lamanna, Nicole, Alonso, Rosalia, Osorio-Prendes, Santiago, Vitale, Candida, Kamdar, Manali, Baltasar, Patricia, Österborg, Anders, Hanson, Lotta, Baile, Mónica, Rodríguez-Hernández, Ines, Valenciano, Susana, Popov, Viola Maria, Barez Garcia, Abelardo, Alfayate, Ana, Oliveira, Ana C, Eichhorst, Barbara, Quaglia, Francesca M., Reda, Gianluigi, Lopez Jimenez, Javier, Varettoni, Marzia, Marchetti, Monia, Romero, Pilar, Riaza Grau, Rosalía, Munir, Talha, Zabalza, Amaya, Janssens, Ann, Niemann, Carsten U, Perini, Guilherme Fleury, Delgado, Julio, Yanez San Segundo, Lucrecia, Gómez Roncero, Ma Isabel, Wilson, Matthew, Patten, Piers, Marasca, Roberto, Iyengar, Sunil, Seddon, Amanda, Torres, Ana, Ferrari, Angela, Cuéllar-García, Carolina, Wojenski, Daniel, El-Sharkawi, Dima, Itchaki, Gilad, Parry, Helen, Mateos-Mazón, Juan José, Martinez-Calle, Nicolas, Ma, Shuo, Naya, Daniel, Van Der Spek, Ellen, Seymour, Erlene K., Gimeno Vázquez, Eva, Rigolin, Gian Matteo, Mauro, Francesca Romana, Walter, Harriet S, Labrador, Jorge, De Paoli, Lorenzo, Laurenti, Luca, Ruiz, Elena, Levin, Mark-David, Šimkovič, Martin, Špaček, Martin, Andreu, Rafa, Walewska, Renata, Perez-Gonzalez, Sonia, Sundaram, Suchitra, Wiestner, Adrian, Cuesta, Amalia, Broom, Angus, Kater, Arnon P., Muiña, Begoña, Velasquez, César A, Ujjani, Chaitra S., Seri, Cristina, Antic, Darko, Bron, Dominique, Vandenberghe, Elisabeth, Chong, Elise A., Lista, Enrico, García, Fiz Campoy, Del Poeta, Giovanni, Ahn, Inhye, Pu, Jeffrey J., Brown, Jennifer R, Soler Campos, Juan Alfonso, Malerba, Lara, Trentin, Livio, Orsucci, Lorella, Farina, Lucia, Villalon, Lucia, Vidal, Maria Jesus, Sanchez, Maria Jose, Terol, Maria Jose, De Paolis, Maria Rosaria, Gentile, Massimo, Davids, Matthew S., Shadman, Mazyar, Yassin, Mohamed A, Foglietta, Myriam, Jaksic, Ozren, Sportoletti, Paolo, Barr, Paul M., Ramos, Rafael, Santiago, Raquel, Ruchlemer, Rosa, Kersting, Sabina, Huntington, Scott F., Herold, Tobias, Herishanu, Yair, Thompson, Meghan C., Lebowitz, Sonia, Ryan, Christine, Jacobs, Ryan W., Portell, Craig A., Isaac, Krista, Rambaldi, Alessandro, Nabhan, Chadi, Brander, Danielle M., Montserrat, Emili, Rossi, Giuseppe, Garcia-Marco, Jose A., Sr., Coscia, Marta, Malakhov, Nikita, Fernandez-Escalada, Noemi, Skånland, Sigrid Strand, Coombs, Callie C., Ghione, Paola, Schuster, Stephen J., Foà, Robin, Cuneo, Antonio, Bosch, Francesc, Stamatopoulos, Kostas, Ghia, Paolo, Mato, Anthony R., and Patel, Meera

Published
2020
Full Text
View/download PDF

32. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab

Author

Vallejo, Carlos, Ríos, Eduardo, de la Serna, Javier, Jarque, Isidro, Ferrá, Christelle, Sánchez-Godoy, Pedro, Solano, Carlos, de la Cámara, Rafael, Rosell, Ana Isabel, Varela, Rosario, García, María Dolores, González-Barca, Eva, López, Javier, Pérez, Elena, Ferrer, Secundino, Casado, Luis Felipe, Vázquez, Lourdes, Villalón, Lucía, and García-Marco, José A

Published
2011
Full Text
View/download PDF

33. Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells

Author

Aguilera-Montilla, Noemí, primary, Bailón, Elvira, additional, Ugarte-Berzal, Estefanía, additional, Uceda-Castro, Rebeca, additional, Prieto-Solano, María, additional, García-Martínez, Elena, additional, Samaniego, Rafael, additional, Van den Steen, Philippe E., additional, Opdenakker, Ghislain, additional, García-Marco, José A., additional, and García-Pardo, Angeles, additional

Published
2019
Full Text
View/download PDF

34. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

Author

García-Marco, José A, Jiménez, Javier López, Recasens, Valle, Zarzoso, Miguel Fernández, González-Barca, Eva, De Marcos, Nieves Somolinos, Ramírez, M Jose, Parraga, Francisco Javier Peñalver, Yañez, Lucrecia, De La Serna Torroba, Javier, Malo, Maria Dolores Garcia, Ariznavarreta, Guillermo Deben, Persona, Ernesto Perez, Guinaldo, M Angeles Ruiz, De Paz Arias, Raquel, Llanos, Elena Bañas, Jarque, Isidro, Valle, M Del Carmen Fernandez, Tatay, Ana Carral, De Oteyza, Jaime Perez, Martin, Eva Maria Donato, Fernández, Inmaculada Perez, Martinez, Rafael Martinez, Costa, M Angeles Andreu, Champ, Diana, Suarez, Julio García, Díaz, Marcos González, Ferrer, Secundino, Carbonell, Félix, García-Vela, José A, GELLC Study Group, and Roche

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Neoplasm, Residual, Cyclophosphamide, Chronic lymphocytic leukemia, Population, Article, Maintenance Chemotherapy, Maintenance therapy, Chemoimmunotherapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Chronic Lymphocytic Leukemia, education, Aged, education.field_of_study, business.industry, Remission Induction, Hematology, Middle Aged, medicine.disease, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Fludarabine, Treatment Outcome, Tolerability, Rituximab, Female, business, Vidarabine, medicine.drug
Abstract

© 2019 Ferrata Storti Foundation., It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this study, we analyzed the outcome of 84 patients at 3 years of follow-up after first-line treatment with fludarabine, cyclophosphamide and rituximab (FCR) induction followed by 36 months of rituximab maintenance thearpy. MRD was assessed by a quantitative four-color flow cytometry panel with a sensitivity level of 10-4. Eighty out of 84 evaluable patients (95.2%) achieved at least a partial response or better at the end of induction. After clinical evaluation, 74 patients went into rituximab maintenance and the primary endpoint was assessed in the final analysis at 3 years of follow-up. Bone marrow (BM) MRD analysis was performed after the last planned induction course and every 6 months in cases with detectable residual disease during the 36 months of maintenance therapy. Thirty-seven patients (44%) did not have detectable residual disease in the BM prior to maintenance therapy. Interestingly, 29 patients with detectable residual disease in the BM after induction no longer had detectable disease in the BM following maintenance therapy. After a median followup of 6.30 years, the median overall survival (OS) and PFS had not been reached in patients with either undetectable or detectable residual disease in the BM, who had achieved a complete response at the time of starting maintenance therapy. Interestingly, univariate analysis showed that after rituximab maintenance OS was not affected by IGHV status (mutated vs. unmutated OS: 85.7% alive at 7.2 years vs. 79.6% alive at 7.3 years, respectively). As per protocol, 15 patients (17.8%), who achieved a complete response and undetectable peripheral blood and BM residual disease after four courses of induction, were allowed to stop fludarabine and cyclophosphamide and complete two additional courses of rituximab and continue with maintenance therapy for 18 cycles. Surprisingly, the outcome in this population was similar to that observed in patients who received the full six cycles of the induction regimen. These data show that, compared to historic controls, patients treated with FCR followed by rituximab maintenance have high-quality responses with fewer relapses and improved OS. The tolerability of this regime is favorable. Furthermore, attaining an early undetectable residual disease status could shorten the duration of chemoimmunotherapy, reducing toxicities and preventing long-term side effects. The analysis of BM MRD after fludarabine-based induction could be a powerful predictor of post-maintenance outcomes in patients with CLL undergoing rituximab maintenance and could be a valuable tool to identify patients at high risk of relapse, influencing further treatment strategies., This work was funded by Roche Farma, S.A., Madrid, Spain

Published
2019

35. Propuesta de Plan de adaptación de las instalaciones del Grupo de Caballería Ligero Acorazado 'Reyes Católicos' II de La Legión a la Brigada Experimental 2035

Author

García Marco, José María, León Calero, José Juan, and Sancho Val, José Joaquín

Abstract

El Ejército de Tierra está llevando a cabo un importante proyecto, denominado Fuerza 2035, para hacer frente a los cambios que conlleva el futuro. Para desarrollarlo se basa en la experimentación, y para ello cuenta con la Brigada Experimental 2035. Este Trabajo de Fin de Grado se centra en el Grupo de Caballería de esta Brigada Experimental 2035. El Grupo designado para ello, es el Grupo de Caballería Ligero Acorazado “Reyes Católicos” II de La Legión.Las adaptaciones que debe llevar a cabo el Grupo de Caballería, como Grupo experimental, son muy diversas y complejas, que van cambiando según avanza el tiempo. Uno de los mayores retos que tiene el Grupo, es la adaptación de sus instalaciones a la nueva orgánica, nuevos materiales y nuevas plataformas, ya que esta tarea depende directamente de la Unidad, y se le va a exigir que de capacidad a los nuevos conceptos que se le van a integrar por pertenecer a la Brigada Experimental 2035. Para llevar a cabo una propuesta de las instalaciones, es indispensable realizar un estudio, tanto de la situación actual, de cómo se encuentra a día de hoy las capacidades del Grupo, tanto de la situación que se espera del Grupo dentro de la Brigada Experimental 2035. Posteriormente, tras haber realizado una comparativa de dichas situaciones y analizado el resultado, se podrá establecer que instalaciones requieren de una reestructuración, reforma o directamente si son necesarias instalaciones de obra nueva. Esto dará lugar al Plan de adaptación propuesto. Este, define los requisitos que deben cumplir dichas instalaciones para una correcta adaptación del Grupo, no solo en cuanto al personal, las nuevas plataformas y materiales, sino también a los conceptos básicos que establece el proyecto Fuerza 2035.Así, este Trabajo de Fin de Grado presenta una propuesta de Plan de adaptación de las instalaciones del Grupo de Caballería Ligero Acorazado “Reyes Católicos” II de La Legión a la Brigada Experimental 2035. Esta propuesta, deja abierta diferentes líneas futuras para que se pueda llegar a ejecutar una adaptación real, con diferentes posibilidades para llevarla a cabo.

Published
2019

37. Prostatic-Like Syndrome in a Woman with Chronic Lymphocytic Leukemia: Sequential Kinase Inhibitor Therapy

Author

Velasco-Rodríguez, Diego, Piris-Villaespesa, Miguel, Soteras, Carmen, Vallés, Ana, García-Marco, José Antonio, and García-Vela, José Antonio

Subjects
Article Subject, immune system diseases, hemic and lymphatic diseases
Abstract

Chronic lymphocytic leukemia (CLL) is an incurable lymphoproliferative disorder with a heterogeneous genetic and clinical course. Two kinase inhibitors, ibrutinib and idelalisib, have demonstrated achievement of complete and durable remissions in relapse/refractory genetically unselected CLL patients. We present a case of relapsed CLL with extensive disease and hourglass deformity of urinary bladder as a result of the compression of two extraperitoneal paravesical soft tissue bulky masses, with excellent response to sequential kinase inhibitor therapy.

Published
2017
Full Text
View/download PDF

41. Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma NOS Diagnosis: Comparative Study between PET, Histology and Flow Cytometry

Author

Martin Moro, Fernando, Piris-Villaespesa, Miguel, Marquet Palomanes, Juan, Lopez Prieto, Claudia, Herrera, Federico Santiago, Delgado Trillo, Maria Isabel, Garcia-Cosio, Monica, Martinez Lorca, Alberto, Lario Arribas, Ana, Roldan Santiago, Ernesto, Rodriguez Martin, Eulalia, Garcia-Marco, Jose A., Sr., Lopez Jimenez, Javier, and Garcia Vela, Jose Antonio

Published
2020
Full Text
View/download PDF

42. Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Author

Abrisqueta, Pau, González-Barca, Eva, Ferra, Christelle M, Ríos Herranz, Eduardo, Fernandez, Margarita, Delgado, Julio, Andreu, Rafael, Hernandez-Rivas, Jose Angel, Terol, Maria Jose, González, Marcos, Baltasar Tello, Patricia, de la Serna, Javier, Ramirez Payer, Angel, Ballester, Carmen, Moreno, Carol, Garcia-Marco, Jose A., Cordoba, Raul, Yanez San Segundo, Lucrecia, Casado Montero, Luis Felipe, and Bosch, Francesc

Published
2019
Full Text
View/download PDF

43. Actualización de las guías nacionales de consenso del Grupo Español de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónica

Author

García-Marco, José A., primary, Delgado, Julio, additional, Hernández-Rivas, José A., additional, Ramírez Payer, Ángel, additional, Loscertales Pueyo, Javier, additional, Jarque, Isidro, additional, Abrisqueta, Pau, additional, Giraldo, Pilar, additional, Martínez, Rafael, additional, Yáñez, Lucrecia, additional, Terol, Mª José, additional, González, Marcos, additional, and Bosch, Francesc, additional

Published
2017
Full Text
View/download PDF

44. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia

Author

García-Marco, José A., primary, Delgado, Julio, additional, Hernández-Rivas, José A., additional, Ramírez Payer, Ángel, additional, Loscertales Pueyo, Javier, additional, Jarque, Isidro, additional, Abrisqueta, Pau, additional, Giraldo, Pilar, additional, Martínez, Rafael, additional, Yáñez, Lucrecia, additional, Terol, M. José, additional, González, Marcos, additional, and Bosch, Francesc, additional

Published
2017
Full Text
View/download PDF

46. Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells

Author

Sánchez-Martínez, Diego, primary, Lanuza, Pilar M., additional, Gómez, Natalia, additional, Muntasell, Aura, additional, Cisneros, Elisa, additional, Moraru, Manuela, additional, Azaceta, Gemma, additional, Anel, Alberto, additional, Martínez-Lostao, Luis, additional, Villalba, Martin, additional, Palomera, Luis, additional, Vilches, Carlos, additional, García Marco, José A., additional, and Pardo, Julián, additional

Published
2016
Full Text
View/download PDF

47. Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Author

Pavlova, Sarka, Malcikova, Jitka, Radova, Lenka, Bonfiglio, Silvia, Cowland, Jack B., Brieghel, Christian, Andersen, Mette Klarskov, Karypidou, Maria, Biderman, Bella V, Doubek, Michael, Lazarian, Gregory, Rapado, Inmaculada, Vynck, Matthijs, Porret, Naomi, Andres, Martin, Rosenberg, Dina, Sahar, Dvora, Martinez-Laperche, Carolina, Borde, Ismael Buño, Hindley, Andrew, Sánchez, Julio Bravo, García-Marco, José, Serrano, Alicia, Ferrer Lores, Blanca, Fernández-Rodriguez, Concepción, Bellosillo, Beatriz, Stilgenbauer, Stephan, Tausch, Eugen, Nikdin, Hero, Quinn, Fiona, Atkinson, Emer, Van De Corput, Lisette, Yildiz, Cafer, Bilbao, Cristina, Florido, Yanira, Thiede, Christian, Schuster, Caroline, Stoj, Anastazja, Czekalska, Sylwia, Chatzidimitriou, Anastasia, Laidou, Stamatia, Bidet, Audrey, Dussiau, Charles, Nollet, Friedel, Piras, Giovanna, Borosova, Tereza, Kurucova, Terezia, Monne, Maria, Smirnova, Svetlana, Nikitin, Evgeny, Sloma, Ivan, Delfau, Marie-Helene, Largeaud, Laetitia, Ysebaert, Loic, Valk, Peter J. M., Christian, Amy, Walewska, Renata, Sebastião, Marta, da Silva, Maria Gomes, Galieni, Piero, Angelini, Mario, Rossi, Davide, Spina, Valeria, Matos, Sónia, Martins, Vânia, Donaldson, David, Stoklosa, Tomasz, Pepek, Monika, Baliakas, Panagiotis, Andreu, Rafa, Luna, Irene, Kahre, Tiina, Murumets, Ülle, Laird, Sophie, Ward, Daniel, Alcoceba, Miguel, Balanzategui, Ana, Scarfo, Lydia, Gandini, Francesca, Zapparoli, Ettore, Blanco, Adoracion, Costa, Pau Abrisqueta, Rodriguez, Ana E., Benito Sanchez, Maria Rocio, Davi, Frédéric, Bravetti, Clothilde, Gameiro, Paula, Martinez-Lopez, Joaquin, Tazon, Barbara, Baran-Marszak, Fanny, Davies, Zadie, Caterwood, Mark, Sudarikov, Andrey B, Rosenquist, Richard, Niemann, Carsten Utoft, Stamatopoulos, Kostas, Ghia, Paolo, and Pospisilova, Sarka

Abstract

The presence of mutations in the TP53gene is a powerful prognostic and predictive marker in chronic lymphocytic leukemia (CLL). Widespread use of NGS has enabled the detection of variants ≤10 % variant allelic frequency (low-VAF variants); however, the overall reliability and reproducibility of NGS techniques to identify such variants have been questioned repeatedly. Individual studies using sensitive, custom NGS-based assays have mostly demonstrated the shortened overall survival (OS) and event-free survival in patients with low-VAF TP53variants treated with chemoimmunotherapy (CIT) regimens with median survival ranging between that of TP53 variants >10 % VAF (high-VAF) and wild-type TP53(wt- TP53).

Published
2023
Full Text
View/download PDF

50. Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica

Author

Casado, Luis Felipe, García Marco, José Antonio, Gilsanz, Florinda, González, Marcos, Ríos, Eduardo, Serna, Javier de la, Urbano, Álvaro, Vicente, Vicente, Rubio-Terrés, Carlos, and Castro, Antonio J.

Subjects
Fludarabine, Coste-efectividad, Chronic lymphocytic leukemia, Cost-effectiveness, Ciclofosfamida, Rituximab, Fludarabina, Cyclophosphamide, Leucemia linfática crónica
Abstract

Objetivos: Evaluar el coste-efectividad del esquema de rituximab, fludarabina y ciclofosfamida (R-FC) en comparación con el de fludarabina y ciclofosfamida (FC) en dos tipos de pacientes con leucemia linfática crónica (LLC): no tratados previamente o bien en recidiva/resistentes al tratamiento previo. Métodos: Dos modelos de Markov, utilizando los resultados publicados de superviviencia libre de progresión (SLP) de pacientes con LLC tratados con R-FC o FC en primera o segunda línea, las tasas de progresión de la enfermedad y las tasas de mortalidad en España. A los estados de SLP y progresión se les asignaron utilidades obtenidas en un estudio sobre LLC. Los costes de los medicamentos y de los tratamientos de soporte, así como los años de vida ajustados por calidad (AVAC), se estimaron para un periodo de 10 años. Se efectuaron análisis de sensibilidad univariados y probabilísticos (Monte Carlo). Resultados: La adición de rituximab a la quimioterapia con FC aumentó los años de vida ganados (AVG) y los AVAC tanto en primera como en segunda línea de tratamiento. La razón de coste-eficacia incremental fue de 20.703 € por AVG y de 19.343 € por AVAC con la primera línea de tratamiento, y de 23.183 € por AVG y 24.781 € por AVAC con la segunda línea de tratamiento. Conclusiones: En los pacientes con LLC no tratados previamente y en aquellos en recaída o resistentes al tratamiento previo, la adición de rituximab al esquema FC aumentó la esperanza de vida y los AVAC, y en ambos casos resultó ser un tratamiento coste-efectivo. Objectives: We evaluated the cost-effectiveness of rituximab added to the chemotherapy regimen of fludarabine plus cyclophosphamide (R-FC) versus fludarabine plus cyclophosphamide (FC) for the treatment of patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). Methods: Two Markov models were built, using published results on progression-free survival (PFS) in patients receiving first- or second-line therapy with R-FC vs FC, rates of disease progression and mortality rates in Spain. Patient-elicited utilities were applied to PFS and progressed health states. The cost of drugs, supportive care, and quality-adjusted life years (QALY) were estimated over a 10-year period. Univariate and probabilistic (Monte Carlo) sensitivity analyses were performed. Results: The addition of rituximab to chemotherapy in first- and second-line therapy increased life-years gained (LYG) and QALYs compared with chemotherapy. The incremental cost per LYG and QALY gained was €20,703 and €19,343 for first-line treatment and was €23,183 and €24,781 for second-line treatment. Conclusion: In patients with previously untreated or relapsed/refractory CLL, the addition of rituximab to the FC regimen increased life expectancy and quality-adjusted life expectancy. In both types of patient, the treatment was cost-effective.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results